Opthea Wet AMD Data Featured at Macula Society Meeting

Core Viewpoint - Opthea Limited is set to present data on its lead product candidate, sozinibercept, at the Macula Society's 48th Annual Meeting, highlighting its potential advantages over standard treatments for wet age-related macular degeneration (wet AMD) [1][2]. Group 1: Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet AMD and diabetic macular edema (DME), which are significant causes of vision loss globally [3][4]. - The company's lead product candidate, sozinibercept, is a first-in-class VEGF-C/D 'trap' inhibitor currently in Phase 3 development [4]. Group 2: Presentation Details - The presentation titled "Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study to Assess the Angiographic Predictors of Response" will take place on February 14, 2025, from 8:00 to 8:05 AM ET [2]. - Dr. David S. Boyer will present findings indicating that sozinibercept 2 mg combination therapy resulted in superior vision and anatomical outcomes compared to the standard-of-care treatment, ranibizumab [2].